3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Lymphoid
6
Gastrointestinal
2
Thoracic
1
Other
1
Gynecologic
1
Genitourinary
1
Dermatologic
1
Classical hematology
1
Conditions
Melanoma
862
Lymphoma, T-Cell, Cutaneous
143
Uveal Melanoma
97
Skin Neoplasms
96
Mycosis Fungoides
95
Sezary Syndrome
81
Carcinoma, Basal Cell
76
Neoplasm Metastasis
68
Lymphoma
64
Lymphoma, Non-Hodgkin
63
Keratosis, Actinic
61
Neoplasms
57
Leukemia, Lymphocytic, Chronic, B-Cell
57
Carcinoma, Renal Cell
55
Carcinoma, Non-Small-Cell Lung
54
Lymphoma, B-Cell, Marginal Zone
53
Precursor Cell Lymphoblastic Leukemia-Lymphoma
52
Lymphoma, Mantle-Cell
52
Lymphoma, Large B-Cell, Diffuse
52
Lymphoma, Follicular
52
Hodgkin Disease
52
Lymphoma, Large-Cell, Immunoblastic
50
Carcinoma, Merkel Cell
50
Burkitt Lymphoma
49
Brain Neoplasms
46
Multiple Myeloma
44
Lymphoma, Large-Cell, Anaplastic
41
Recurrence
40
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
40
Breast Neoplasms
40
Interventions
pembrolizumab
1
Nivolumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
Colitis, Ulcerative
×
Dermatologic
×
Clear all
NCT07223424
2026-04-16
PSI-Immune
University of Pittsburgh
Phase 2
Recruiting
880 enrolled